Skip to Content

Tag: CCS


Arti Masturzo

Specialty Providers

CCS: ‘There’s something about that DME interaction’

September 27, 2024Theresa Flaherty, Managing Editor

DALLAS – People with diabetes fall off their therapy all the time for a variety of reasons, but DME providers are best equipped to catch them when they do, according to the results of a new study conducted by CCS.  DME patients reinitiated their use of continuous glucose monitors 22% of the time compared to 10% of pharmacy patients, the study found.  “I didn’t expect the difference to be that big,” said Dr. Arti Masturzo, chief medical officer at CCS. “People...

CCS, Continuous Glucose Monitor (CGM), Diabetes


Read Full Articlered right arrow icon

News

In brief: CGM outcomes, Vent360+ launch, O&P WOY, AdaptHealth refi 

September 18, 2024HME News Staff

DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMID).  Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs. pharmacy...

AdaptHealth, CCS, Continuous Glucose Monitor (CGM), Diabetes, Encore Healthcare, O&P Woman of the Year, Trace Medical


Read Full Articlered right arrow icon

Study: Using medical benefit can result in positive outcomes  

Specialty Providers

Study: Using medical benefit can result in positive outcomes  

September 17, 2024HME News Staff

DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes).  Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs....

Adherence, CCS, Continuous Glucose Monitor (CGM), Cost of Care, Diabetes, Research


Read Full Articlered right arrow icon

Richard Mackey

Specialty Providers

CCS sees AI tool as next step in diabetes care evolution

June 21, 2024Theresa Flaherty, Managing Editor

DALLAS – The volume of data being collected from diabetes patients presents an opportunity to use artificial intelligence to better understand which patients are at risk for non-adherence to therapy, says Richard Mackey, chief technology officer at CCS, which recently launched PropheSee, an AI-powered predictive model for CGM users.  “We want to deliver insights that help them anticipate whatever needs they might have (and identify) situations where some additional support or...

CCS, Continuous Glucose Monitor (CGM), Diabetes, PropheSee


Read Full Articlered right arrow icon

News

In brief: CCS launches PropheSee, Vertess’ Smith recognized

June 12, 2024HME News Staff

DALLAS – CCS has launched PropheSee, an AI-powered predictive model for health care organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.  With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk...

CCS, Edgepark, Medtrade, Nymbl Systems, PropheSee, Vertess


Read Full Articlered right arrow icon

Specialty Providers

CCS Launches AI-powered model

June 11, 2024HME News Staff

DALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.  With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification,...

Artificial Intelligence (AI), CCS, Diabetes, PropheSee


Read Full Articlered right arrow icon

Also Noted

Promotions: Encore Health, CCS

April 25, 2024HME News Staff

LIVINGSTONE, Tenn. – Encore Healthcare has promoted Carrie Proffitt, RRT, to senior vice president of operations. Over the last few years, her role has evolved from clinical operations to overall operations of Encore’s software and service business lines. In her previous role as vice president of clinical operations, Proffitt demonstrated exceptional leadership, dedication and a deep commitment to Encore's mission, the company says.  Dallas-based CCS has named Scott Streator...

CCS, Encore Healthcare


Read Full Articlered right arrow icon

News

In brief: Medtrade’s attendance, CCS’s CVS Health hire 

March 29, 2024HME News Staff

DALLAS – Medtrade officials say attendance at the industry’s annual trade show increased 25% this year compared to last year. “This year’s Medtrade attracted more than 2,300 qualified attendees,” said Kerry Tyler, associate show director. The show drew attendees from every state except Rhode Island and from 35 countries, officials say. As part of the New Product Awards sponsored by HomeCare Media at Medtrade, attendees selected Jover Walker Cover by Jover for Providers’...

2024, CCS, Medtrade


Read Full Articlered right arrow icon

Arti Masturzo

Specialty Providers

CCS ‘on right track’ 

March 13, 2024Theresa Flaherty, Managing Editor

GLP-1 medications misconception: Nearly 60% of diabetes patients surveyed by CCS mistakenly believe that GLP-1 medications alone are a silver bullet for managing their health. However, these drugs need to be integrated into a long-term holistic care plan.  Education and support gap: The survey results highlight a real need for better education and support for patients managing their diabetes. Diabetes suppliers are well-positioned to...

CCS, Coaching, Diabetes, Education, GLP-1


Read Full Articlered right arrow icon

News

In brief: AAH on cath fraud & CCS on GLP-1s

March 8, 2024HME News Staff

WASHINGTON – AAHomecare has issued a statement affirming its support for the government to implement real-time monitoring of claims to detect potential fraud and abuse, in response to news reports of potential Medicare fraud by a handful of intermittent catheter companies.  AAHomecare's statement, which was shared with CMS and Capitol Hill, also reiterates recommendations for federal government initiatives to better monitor DME supplier billing practices and trends, including:  Increased...

AAHomecare, Catheter, CCS, Diabetes, Noridian, Soleo Health


Read Full Articlered right arrow icon